Knowledge of the pituitary thyroid relation was developed shortly after the pioneer experiments with hypophysectomy in the rat by the pharyngeal approach (Smith 1927) . Removal of the pituitary without injury to the brain established both the trophic role of the anterior lobe over the thyroid as well as over the other endocrine glands and the reciprocal relationship between the pituitary and its target organs. Although the hypothalamus appeared to be eliminated from consideration, the possibility has been reintroduced (Harris & Woods 1958 ) that this area functions as a regulator of pituitary secretion.
For thyrotrophin in particular, radiothyroxine was shown to have an affinity for the hypothalamus and posterior pituitary (Courrier et al. 1951) and localized destruction of the antero-medial part of the third ventricle was shown to reduce thyrotrophin release to a minimum (Greer 1952) . The more recent claim that thyroxine injected into the anterior hypothalamus suppresses release of thyrotrophin (Yamada et al. 1961) , has also been interpreted as an action on the anterior pituitary rather than an action locally, due to the thyroxine being brought there from the site of injection by the portal circulation (Bogdanove & Crabill 1961) .
The following presentation omits the hypothalamic component of the pituitary-thyroid relation and stresses the author's own work. No effort has been made to document the available literature.
The experimental administration of excess of the early pituitary thyrotrophin preparations revealed that intense stimulation of the thyroid was induced which subsided spontaneously after several weeks despite continuation of the injections (Collip & Anderson 1934) . The serum of such refractory animals was then capable of neutralizing thyrotrophic extract when both were injected into another animal. This led to the 'antihormone' hypothesis, that a physiological "Much of the author's work cited was done with the aid of grants A8 (Cl-13 inc.), Division of Arthritis and Metabolism, National Institutes of Health antagonist to thyrotrophin (and to the other pituitary trophins) increased in titre in order to preserve homeostasis (Collip & Anderson 1934) .
This theory became untenable when it was found that a flavianic acid preparation of thyrotrophin, unlike the sodium sulphate preparation in common use at that time, did not induce refractoriness (Werner 1 936a). In fact, the flavianate preparation caused a renewed response of the thyroid ofrefractory animals. It thus seemed likely that refractoriness was no more than an immunological response to the thyrotrophin acting as a foreign protein (Werner 1936b) . Interest in the immunology of thyrotrophin, as well as of the other pituitary hormones, has recently had a brisk revival (Ciba Found. Coll. Endocrin. 1962) .
A by-product of the flavianic acid experiments was the opportunity to study the thyroid changes in protracted hyperthyroidism (Werner 1938) . Although the resemblance to the changes of Graves' disease was very close, no lymphocytic infiltration of the experimental gland developed. This discrepancy is possibly now explicable on the basis of an autoimmune response in the clinical disease. However, further tests of the generally accepted view that Graves' disease was due to excessive pituitary secretion of thyrotrophin (Werner et al. 1952 ) have suggested that the pituitary-thyroid relation is indeed disordered but that the evidence is against the presence of an endogenous excess of pituitary thyrotrophin , Werner 1962 .
Lately, a thyrotrophin-like substance, 'longacting thyroid stimulator (LATS)', has been demonstrated in the serum of patients with Graves' disease (Adams & Purves 1957) . This acts later and over a longer period than standard thyrotrophin in the thyroxine-suppressed, l5[Ilabelled, test animal used for assay. The original experience, confirmed by the results in our own laboratory (Werner 1963 ) suggests that LATS is associated more with the eye changes of Graves' disease than with the thyrotoxicosis itself.
Most recently, an extra-pituitary origin of LATS has been suggested by the results of hypophysectomy in two patients with the ocular complications of Graves' disease (McKenzie et al. 1961 , Werner 1962 . Post-operatively, thyroid function was not reduced significantly; and the LATS titre in serum remained high for two and a half months before it gradually disappeared. Clinically, the eye changes showed no improvement until after two and a half months, but the loss of vision present in our own patient was not benefited.
The initial clinical experiments of this laboratory with Graves' disease (Werner et al. 1952) revealed that thyroid 131I uptake was not suppressed when thyroid was administered to patients with active hyperthyroidism until strikingly large doses were given. Decreases in uptake then occurred occasionally. Sodium iodide given in the amounts expected to be derived from the metabolism of these larger doses, however, resulted similarly in an occasional decrease in uptake.
For this reason, triiodothyronine (T3) was substituted for desiccated thyroid or thyroxine, since T3 was active in doses too small to provide enough iodide to affect the thyroid directly. The consistency with which uptake was decreased in euthyroid subjects and not in hyperthyroid patients led to use of the procedure as a test for hyperthyroidism with the advantage mentioned over thyroid for the same purpose (Greer & Smith 1954 , Perlmutter & Slater 1955 . The dose of T3 has now been reduced to 50 ,g instead of the 75 ,ug originally suggested daily for eight days to obviate a real though rare risk of heart failure, anginal pain, or cardiac arrhythmia with larger doses. When confirmation of a result is desirable, however, 75 to 100 ,ug daily may be given for a second week and uptake again determined.
Euthyroid patients with recent onset of eye signs of Graves' disease generally fail to show suppression with T3 (Werner 1955) ; wider experience suggests that about 25% (Guinet & Descour 1962 ) of these have normal responsiveness when first seen. Subsequently, retesting may reveal no response. After remission has been induced in patients with active Graves' disease, failure to show suppression may persist for as much as twenty years or more; or a normal pattern may be restored within a few months of remission (Werner 1956 ). The suggestion has been made that the former group are those apt to have a recurrence of disease but the evidence is weak (Cassidy & VanderLaan 1960) .
Approximately 1 in 4 patients with non-toxic nodular goitre shows lack of suppression following T3 administration , Guinet & Descour 1962 . Scintillation scanning usually reveals the presence of 'hot', autonomous, nodules within the gland. With solitary nodules, particularly, uptake may be limited to the nodule. The contralateral normal thyroid lobe may be functionless due to pituitary suppression from endogenous thyroxine or T3 excess coming from the nodule; uptake is resumed when the offending nodule is removed or thyrotrophin administered.
Efforts to modify, and improve the.T3 suppression test have apparently not gained greater accuracy (Hales et al. 1961 , Hoather & Wooley 1960 . The time of testing has been decreased from eight to four days with some increase in the number of non-hyperthyroid patients showing failure of suppression.
Pituitary suppression by thyroid hormone has been employed therapeutically in non-toxic goitre, chronic thyroiditis, and even papillary thyroid cancer. Revival of interest in this concept is due to Greer and Astwood, and this group (Astwood et al. 1960 ) has reported that, in ten years or more, thyroid cancer did not become clinically evident in any patient with nodular goitre receiving suppressive therapy with thyroid, either by growth of a nodule or by appearance of metastases. In contrast, the whole idea, its efficacy and safety have been strongly challenged (Sloan & Frantz 1962) . The carefully controlled studies and the complete follow-up observations needed to resolve the debate are still wanting. Known thyroid papillary cancer has been held in check for some years by suppressive therapy but escape eventually occurs in about half (Thomas 1963) . The course of disease without therapy also shows remarkable spontaneous fluctuations.
Triiodothyronine offers an advantage over thyroxine or thyroid in suppressive therapy. The T3 binds poorly with thyroxine-binding interalpha globulin and so does not result in an increased level of P.B.I. when administered. The extent of pituitary suppression can thus be gauged by the drop in level of P.B.I. or serum thyroxine.
One patient reveals well the problems inherent in appraising the usefulness of pituitary suppressive therapy:
A man of 37 had a total thyroidectomy for papillary cancer in 1945. Thyroid was first given in 1954 when a 1 x 0 5 cm nodule appeared superior to and near the stemoclavicular junction. On T4 400,ug daily and later T3 100,lg, the nodule slowly increased in size reaching approximately 4 x 2 x 1 cm. Operation was finally accepted (May 1962) and typical non-toxic nodular goitre was found in the palpable mass. However, microscopic foci of papillary cancer were identified in the pretracheal lymph nodes.
Meeting February 281962 heldjointly with the Society for Endocrinology and the Society for the Study ofFertility (continuedfrom October 'Proceedings' p 868) The following papers were also read: Lancet, 1962, i, 407) For abstracts of these papers see J. Endocrin., 1962, 24, i-xxxii 
